摘要
目的探讨不同的干细胞移植法对白血病患者血浆触珠蛋白(Hp)变化的影响。方法以4例进行间充质干细胞和造血干细胞共移植(MSC/HSCT)的患者和2例采用造血干细胞移植(HSCT)的患者为研究对象,运用双向凝胶电泳(2-DE)对其不同治疗阶段的血浆中的触珠蛋白进行分离,利用MALDI-TOF/TOF MS进行鉴定。结果治疗过程中触珠蛋白β链和α链的血浆含量在移植后呈现明显的递减趋势,并伴有多种翻译后修饰,这种变化趋势在MSC/HSCT治疗的患者中更为显著。结论触珠蛋白有可能成为白血病干细胞移植治疗疗效评价及疗程监测的标志物。
Objective To explore the effects of different approaches of stem cell therapy in patients with leukemia on haptoglobin（Hp）.Methods The trial includes four patients treated by mesenchymal stem cell（MSC） with hematopoietic stem cell cotransplantation（HSCT） and two patients treated by hematopoietic stem cell transplantation（HSCT）.Haptoglobin in the plasma,collected from different therapeutic stages,of six patients was separated by two-dimensional gel electrophoresis（2-DE）,and then followed by the identification with MALDI-TOF/TOF mass spectrometry.Results The abundance of haptoglobin alpha and beta chains with different modifications decreased along with an extending therapeutic time window.This tendency was more significant in HSCT group.Conclusion The haptoglobin may be a potential biomarker for the prognosis in patients with leukemia treated by stem cell transplantation.
出处
《基础医学与临床》
CSCD
北大核心
2010年第5期454-458,共5页
Basic and Clinical Medicine
基金
国家自然科学基金(20675088)
国家863计划(2006AA02A109)
北京市自然科学基金(7062042)
